Shares of Magenta Therapeutics, Inc. (NASDAQ:MGTA – Get Rating) have been assigned an average rating of “Hold” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $5.00.
A number of research analysts have recently commented on the stock. BTIG Research cut shares of Magenta Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, January 26th. Wedbush downgraded shares of Magenta Therapeutics from an “outperform” rating to a “neutral” rating in a report on Thursday, January 26th. Cowen restated a “market perform” rating on shares of Magenta Therapeutics in a research note on Thursday, January 26th. Finally, HC Wainwright began coverage on Magenta Therapeutics in a report on Tuesday. They set a “neutral” rating for the company.
Insider Transactions at Magenta Therapeutics
In other news, major shareholder Rock Ventures Iv L.P. Third sold 2,200,000 shares of the business’s stock in a transaction dated Tuesday, February 7th. The stock was sold at an average price of $0.83, for a total value of $1,826,000.00. Following the completion of the sale, the insider now directly owns 4,558,204 shares of the company’s stock, valued at approximately $3,783,309.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 15.18% of the company’s stock.
Hedge Funds Weigh In On Magenta Therapeutics
Magenta Therapeutics Stock Up 0.6 %
Shares of MGTA stock opened at $0.80 on Tuesday. The firm has a market cap of $48.45 million, a PE ratio of -0.63 and a beta of 2.10. The company’s fifty day simple moving average is $0.61 and its 200-day simple moving average is $1.10. Magenta Therapeutics has a 12 month low of $0.32 and a 12 month high of $3.62.
About Magenta Therapeutics
Magenta Therapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of novel medicines for bone marrow transplants. It offers patient preparation, stem cell collection, cell dose, and safe immune regeneration programs. Its platform include autologous and allogeneic transplant, and gene therapy.
- Get a free copy of the StockNews.com research report on Magenta Therapeutics (MGTA)
- Hormel Hits 2-Year Low, And The Dip Gets Bought
- Here’s Why Ross Could Soon Be Hitting All Time Highs
- The Bottom Is In For Salesforce.com
- It’s Time For A Fresh Look At The Kroger Co.
- West Fraser’s Earnings Scream Timber, Outlook Says Buy
Receive News & Ratings for Magenta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magenta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.